drugset / Trial / NCT02308644

Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

NCT02308644 ↗

Phase 3 Completed 41 enrolled University of Sao Paulo
RandomizedCrossoverSingle-blindTreatment

Summary

To evaluate the effects on contrast sensitivity (CS) measurements of intravitreal bevacizumab injections associated with standard metabolic control in eyes with diabetic macular edema (DME) associated with standard metabolic control.

Timeline

Start
2009-02
Primary completion
2011-12
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal